JP Morgan Chase’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

JP Morgan Chase’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-50,000	Closed	-$15.8M	–	8035
2023 Q4	$15.8M	Buy	+50,000	New	+$9.72M	﹤0.01%	2039
2023 Q3	–	Sell	-130,000	Closed	-$28.2M	–	7802
2023 Q2	$28.2M	Buy	+130,000	New	+$27.9M	﹤0.01%	1449
2023 Q1	–	Sell	-5,600	Closed	-$1.1M	–	7369
2022 Q4	$1.1M	Buy	+5,600	New	+$1.2M	﹤0.01%	3971

Other funds holding KRTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

JP Morgan Chase's KRTX Position: Q1 2024 in Review

JP Morgan Chase sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 30,552 shares — an estimated $9.67M sold.

JP Morgan Chase first reported a position in KRTX in Q2 2019 and held it in 19 quarters. The position peaked at $13.4M in Q2 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

JP Morgan Chase reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
JP Morgan Chase sold 30,552 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $9.67M.
JP Morgan Chase first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and held it in 19 quarters.
JP Morgan Chase's Karuna Therapeutics, Inc. Common Stock position peaked at $13.4M in Q2 2023.
2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on JP Morgan Chase's 13F filing for Q1 2024, filed 10 May 2024.